A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease — STEM-PD

Parkinson Disease Clinical Trial

Official title:
STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)

Status Recruiting

Clinical Trial Summary

Parkinson's disease (PD) occurs when an area of the brain begins to lose nerve cells that produce a chemical called dopamine. Dopamine is an important chemical, and one of its functions is that it helps to regulate body movement. The loss of these nerve cells leads to a reduction of dopamine in the brain. Medications used to treat PD temporarily replace this lost dopamine, but they do not repair the underlying disease. One of the most promising PD therapies to date has been the transplantation of dopamine producing cells into the brain. Unlike current treatments, these therapies may be able to repair the damage caused in PD. In this trial, the investigators will transplant a new stem cell therapy, called the STEM-PD product, into the area of the brain affected in people with PD. These stem cells can develop into many different cell types, including dopamine-producing nerve cells. The investigators will transplant the stem cells using a device that has been previously used for similar transplants in Lund. This is the first time that the STEM-PD product will be given to humans. The trial aims to assess whether the STEM-PD product is safe to use in people with PD. The investigators will also be looking for preliminary signs of efficacy. The trial will recruit participants with PD from the UK and Sweden. Eight participants will undergo the STEM-PD product transplant. Participants will receive a single dose of the STEM-PD product. Participants will attend for 25 visits primarily at their local recruiting hospital. For participants from the UK, some of the imaging will be performed at Invicro (London), and the surgery (including some visits before and after) and some imaging will be performed in Lund. All participants will be followed up for 36 months following surgery

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Parkinson Disease

Clinical Trial Details

NCT number	NCT05635409
Study type	Interventional
Source	Region Skane
Contact	Cambridge Clinical Trials Unit - Neuroscience Theme
Phone	+44 (0) 1223 334121
Email	cuh.stempd_trial@nhs.net
Status	Recruiting
Phase	Phase 1
Start date	November 30, 2022
Completion date	June 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05415774` - Combined Deep Brain Stimulation in Parkinson's Disease	N/A
Recruiting	`NCT04691661` - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease	Phase 2
Active, not recruiting	`NCT05754086` - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed	`NCT04045925` - Feasibility Study of the Taïso Practice in Parkinson's Disease	N/A
Recruiting	`NCT04194762` - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation	N/A
Completed	`NCT02705755` - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)	Phase 2
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Recruiting	`NCT05830253` - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting	`NCT03272230` - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System	N/A
Recruiting	`NCT06139965` - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed	`NCT04580849` - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease	N/A
Completed	`NCT03980418` - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam	N/A
Completed	`NCT04477161` - Effect of Ketone Esters in Parkinson's Disease	N/A
Completed	`NCT04942392` - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic	N/A
Terminated	`NCT03446833` - LFP Beta aDBS Feasibility Study	N/A
Completed	`NCT03497884` - Individualized Precise Localization of rTMS on Primary Motor Area	N/A
Completed	`NCT05538455` - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases	N/A
Recruiting	`NCT04997642` - Parkinson's Disease and Movement Disorders Clinical Database
Completed	`NCT04117737` - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson	N/A
Recruiting	`NCT03618901` - Rock Steady Boxing vs. Sensory Attention Focused Exercise	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.